Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 1 , Pages 9-24 , February 2010

Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery

Received 12 January 2009 ,Accepted 28 April 2009.

References 

  1. Asiyanbola B, Soboyejo W. For the surgeon: an introduction to nanotechnology. J Surg Educ. 2008;65:155–161
  2. Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Robert Langer R, Farokhzad OC. New frontiers in nanotechnology for cancer treatment. Urol Oncol. 2008;26:74–85
  3. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine. 2005;1:193–212
  4. Lobenberg R. Smart Materials: Applications of nanotechnology in drug delivery and drug targeting. In: Proceedings of the international conference on MEMS. NANO and Smart Systems (ICMENS'03). 2003;
  5. Kingsley JD, Dou H, Morehead J, Rabinow B, Gendelman HE, Destache CJ. Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol. 2006;1:340–350
  6. Caruthers SD, Wickline SA, Lanza GM. Nanotechnological applications in medicine. Curr Opin Biotechnol. 2007;18:26–30
  7. Mueller RH, Maeder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177
  8. La-Van D, McGuire T, Langer R. Small-scale system for in-vivo drug delivery. Nat Biotechnol. 2003;21:1184–1191
  9. Keck C, Kobierski S, Mauludin R, Muller RH. Second generation of drug nanocrystals for delivery of poorly soluble drugs: smart crystals technology. DSOIS. 2008;24:124–128
  10. Shrivastava S. Nanofabrication for drug delivery and tissue engineering. DJNB. 2008;3:257–263
  11. Muhlen AZ, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery–drug release and release mechanism. Eur J Pharm Biopharm. 1998;45:149–155
  12. Mehnert W, Mader K. Solid lipid nanoparticles—production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–196
  13. Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Lehr CM, et al. Design of rolipram-loaded nanoparticles: comparison of two preparation methods. J Control Release. 2001;71:297–306
  14. Jiang B, Hu L, Gao C, Shen J. Ibuprofen-loaded nanoparticles prepared by a co-precipitation method and their release properties. Int J Pharm. 2005;304:220–230
  15. Chen X, Young TJ, Sarkari M, Williams RO, Johnston KP. Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution. Int J Pharm. 2002;242:3–14
  16. Quintanar-Guerrero D, AlIeman E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm. 1998;24:1113–1128
  17. Allemann E, Leroux JC, Gurny R, Doelker E. In vitro extended release properties of drug-loaded poly (DL-Lactic acid) nanoparticles produced by salting-out procedure. Pharm Res. 1993;10:1732–1737
  18. Toth J, Kardos-Fodor A, Halasz-Peterfi S. The formation of fine particles by salting-out precipitation. Chem Eng Process. 2005;44:193–200
  19. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55:R1–R4
  20. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release. 1999;57:171–185
  21. Moinard-Checot M, Chevalier Y, Briancon S, Beney L, Fessi H. Mechanism of nanocapsules formation by the emulsion–diffusion process. J Colloid Interface Sci. 2008;317:458–468
  22. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification–diffusion technique. Int J Pharm. 2003;257:153–160
  23. Niwa T, Takeuchi H, Hino T, Nohara M, Kawashima Y. Biodegradable submicron carriers for peptide drugs: preparation of DL-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate by a novel emulsion-phase separation method in an oil system. Int J Pharm. 1995;121:45–54
  24. Jung J, Perrut M. Particle design using supercritical fluids: literature and patent survey. J Supercrit Fluids. 2001;20:179–219
  25. Dea SD, Graziani D, Miller DR, Continetti RE. Growth of magnetic thin films using CO2 RESS expansions. J Supercrit Fluids. 2007;42:410–418
  26. Reverchon E, Porta GD, Taddeo R. Solubility and micronization of griseofulvin in supercritical CHF3. Ind Eng Chem Res. 1995;34:4087–4091
  27. Reverchon E, Porta GD. Production of antibiotic micro- and nano-particles by supercritical antisolvent precipitation. Powder Technol. 1999;10:23–29
  28. Chattopadhyay P, Gupta RB. Production of griseofulvin nanoparticles using supercritical CO2 antisolvent with enhanced mass transfer. Int J Pharm. 2001;228:19–31
  29. Chattopadhyay P, Shekunov BY, Seitzinger JS. Particles from supercritical fluid extraction of emulsions (PSFEE): a new method for preparation of nanoparticles of poorly water soluble drugs. Pharm Technol. 2003;1:51–54
  30. Jagannathan R, Irvin G, Blanton T, Jagannathan S. Organic nanoparticles: preparation, self-assembly, and properties. Adv Funct Mater. 2006;16:747–753
  31. Chiellini F, Bartoli C, Dinucci D, Piras AM, Anderson R, Croucher T. Bioeliminable polymeric nanoparticles for proteic drug delivery. Int J Pharm. 2007;343:90–97
  32. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70:1–20
  33. Gomez-Gaete C, Tsapis N, Besnard M, Bochot A, Fattal E. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm. 2007;331:153–159
  34. Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R, et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm. 2006;325:172–179
  35. Jeong YI, Seo SJ, Park IK, Lee HC, Kang IC, Akaike T, et al. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly (γ-benzyl L-glutamate) and poly (ethylene glycol) diblock copolymer endcapped with galactose moiety. Int J Pharm. 2005;296:151–161
  36. Shenoy DB, Amiji MM. Poly (ethylene oxide)-modified poly (γ-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm. 2005;293:261–270
  37. Damge C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release. 2007;117:163–170
  38. Singh J, Pandit S, Bramwell VW, Alpar HO. Diphtheria toxoid loaded poly-(γ-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods. 2006;38:96–105
  39. Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm. 2007;328:191–195
  40. Zhang N, Ping Q, Huang G, Xu W, Cheng Y, Han X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm. 2006;327:153–159
  41. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm. 2008;356:333–344
  42. Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm. 2008;357:295–304
  43. Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm. 2007;345:163–171
  44. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008;127:97–109
  45. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 2007;59:454–477
  46. Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis. 2005;85:415–420
  47. Arruebo M, Fernandez-Pacheco R, Ibarra MR, Santamaria J. Magnetic nanoparticles for drug delivery. Nano Today. 2007;2:22–32
  48. Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng. 2005;100:1–11
  49. Jain TK, Richey J, Strand M, Leslie-Pelecky DL, Flask CA, Labhasetwar V. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials. 2008;29:4012–4021
  50. Jain PK, El-Sayed IH, El-Sayed MA. Au nanoparticles target cancer. Nano Today. 2007;2:18–29
  51. Giljohann DA, Seferos DS, Patel PC, Millstone JE, Rosi NL, Mirkin CA. Oligonucleotide loading determines cellular uptake of DNA-modified gold nanoparticles. Nano Lett. 2007;7:3818–3821
  52. Slowing II, Vivero-Escoto JL, Wu C, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60:1278–1288
  53. Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev. 2008;60:1307–1315
  54. Li D, Li G, Guo W, Li P, Wang E, Wang J. Glutathione-mediated release of functional plasmid DNA from positively charged quantum dots. Biomaterials. 2008;29:2776–2782
  55. Smith AM, Duan H, Mohs AM, Nie S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev. 2008;60:1226–1240
  56. Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O-Regan RM. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol. 2006;7:657–667
  57. Bromberg L. Polymeric micelles in oral chemotherapy. J Control Release. 2008;128:99–112
  58. Bae Y, Diezi TA, Zhao A, Kwon GS. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J Control Release. 2007;122:324–330
  59. Seow WY, Xue JM, Yang Y. Targeted and intracellular delivery of paclitaxel using multi-functional polymeric micelles. Biomaterials. 2007;28:1730–1740
  60. Rapoport N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Prog Polym Sci. 2007;32:962–990
  61. Koo OM, Rubinstein I, Onyuksel H. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine. 2005;1:77–84
  62. Papagiannaros A, Levchenko T, Hartner W, Mongayt D, Torchilin V. Quantum dots encapsulated in phospholipid micelles for imaging and quantification of tumors in the near-infrared region. Nanomedicine. 2009;5(2):216–224
  63. Cesur H, Rubinstein I, Pai A, Onyuksel H. Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. Nanomedicine. 2009;5(2):178–183
  64. Khatri K, Goyal AK, Gupta PN, Mishra N, Mehta A, Vyas SP. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine. 2008;26:2225–2233
  65. Edwards KA, Duan F, Baeumner AJ, March JC. Fluorescently labeled liposomes for monitoring cholera toxin binding to epithelial cells. Anal Biochem. 2008;380:59–67
  66. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691–743
  67. Zhang L, Gao H, Chen L, Wu B, Zheng Y, Liao R, et al. Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells. Cancer Lett. 2008;269:26–36
  68. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release. 1999;62:279–287
  69. Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J Control Release. 2000;65:261–269
  70. Wang N, Wu XS, Li JK. A heterogeneously structured composite based on poly (lactic-co-glycolic acid) micro spheres and poly (vinyl alcohol) hydrogel nanoparticles for long-term protein drug delivery. Pharm Res. 1999;16:1430–1435
  71. Mukerjee A, Sinha VR, Pruthi V. Preparation and characterization of poly-ɛ-caprolactone particles for controlled insulin delivery. J Biomed Pharm Eng. 2007;1:40–44
  72. Pan Y, Li YJ, Zhao HY, Zheng JM, Xu H, Wei G, et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm. 2002;249:139–147
  73. Lin YH, Chung CK, Chen CT, Liang HF, Chen SC, Sung HW. Preparation of nanoparticles composed of chitosan/poly-γ-glutamic acid and evaluation of their permeability through caco-2 cells. Biomacromolecules. 2005;6:1104–1112
  74. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003;8:1112–1120
  75. Galindo-Rodriguez S, Allemann E, Fessi H, Doelker E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Res. 2004;21:1428–1439
  76. Alenso MJ, Losa C, Calvo P, Vila-Jato JL. Approaches to improve the association of amikacin sulphate to poly-(cyanoacrylate) nanoparticles. Int J Pharm. 1991;68:69–76
  77. Nagaoka T, Fukuda T, Yoshida S, Nishimura H, Yu D, Kuroda S, et al. Characterization of bio-nanocapsule as a transfer vector targeting human hepatocyte carcinoma by disulfide linkage modification. J Control Release. 2007;118:348–356
  78. Tsutsui Y, Tomizawa K, Nagita M, Michiue H, Nishiki T, Ohmori I, et al. Development of bionanocapsules targeting brain tumors. J Control Release. 2007;122:159–164
  79. Sunichi K, Takeshi K, Sunichi K, Joohee J, Katsuyuki T. Development of bio-nanocapsules and its applications in the biomedical field. Chem Ind. 2006;57:869–874
  80. Jung J, Matsuzaki T, Tatematsu K, Okajima T, Tanizawa K, Kuroda S. Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials. J Control Release. 2008;126:255–264
  81. Shishido T, Yonezawa D, Iwata K, Tanaka T, Ogino C, Fukuda H, et al. Construction of arginine-rich peptide displaying bionanocapsules. Bioorg Med Chem Lett. 2009;19:1473–1476
  82. Krauland AH, Bernkop-Schnurch A. Thiomers: development and in vitro evaluation of a peroral microparticulate peptide delivery system. Eur J Pharm Biopharm. 2004;57:181–187
  83. Leitner VM, Marschutz MK, Bernkop-Schnurch A. Mucoadhesive and cohesive properties of poly(acrylic acid)-cysteine conjugates with regard to their molecular mass. Eur J Pharm Sci. 2003;18:89–96
  84. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257–1272
  85. Pankhurst QA, Connolly J, Jone SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys. 2003;36:167–181
  86. Briley-Saebo K, Bjornerud A, Grant D, Ahlstrom H, Berg T, Kindberg GM. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res. 2004;316:315–323
  87. Nishijima S, Mishima F, Terada T, Takeda S. A study on magnetically targeted drug delivery system using superconducting magnet. Physica C. 2007;463:1311–1314
  88. Hafeli U, Pauer G, Failing S, Tapolsky G. Radiolabeling of magnetic particles with rhenium-188 for cancer therapy. J Magn Magn Mater. 2001;225:73–78
  89. Chunfu Z, Jinquan C, Duanzhi Y, Yongxian W, Yanlin F, Jiaju T. Preparation and radiolabeling of human serum albumin (HSA)-coated magnetite nanoparticles for magnetically targeted therapy. Appl Radiat Isot. 2004;61:1255–1259
  90. Ally J, Martin B, Khamesee MB, Roa W, Amirfazli A. Magnetic targeting of aerosol particles for cancer therapy. J Magn Magn Mater. 2005;293:442–449
  91. Dames P, Gleich B, Flemmer A, Hajek K, Seidl N, Wiekhorst F. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol. 2007;2:495–499
  92. Martin AR, Finlay WH. Enhanced deposition of high aspect ratio aerosols in small airway bifurcations using magnetic field alignment. Aerosol Sci. 2008;39:679–690
  93. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000;60:6641–6648
  94. Lubbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 1996;56:4694–4701
  95. Alberts DS, Surwit EA, Peng YM, McCloskey T, Rivest R, Graham V, et al. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res. 1988;48:5874–5877
  96. Wuelfing WP, Gross SM, Miles DT, Murray RW. Nanometer gold clusters protected by surface-bound mono-layers of thiolated poly (ethylene glycol) polymer electrolyte. J Am Chem Soc. 1998;12:12696–12697
  97. Oishi M, Nakaogami J, Ishii T, Nagasaki Y. Smart PEGylated gold nanoparticles for the cytoplasmic delivery of siRNA to induce enhanced gene silencing. Chem Lett. 2006;35:1046–1047
  98. Bhumkar DR, Joshi HM, Sastry M, Pokharkar VB. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharm Res. 2007;24:1415–1426
  99. Park C, Oh K, Lee SC, Kim C. Controlled release of guest molecules from mesoporous silica particles based on a pH-responsive polypseudorotaxane motif. Angew Chem Int Ed. 2007;46:1455–1457
  100. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine. 2008;4:273–282
  101. Arya H, Kaul Z, Wadhwa R, Taira K, Hirano T, Kaul SC. Quantum dots in bio-imaging: revolution by the small. Biochem Biophys Res Commun. 2005;329:1173–1177
  102. Hezinger AFE, Tebmar J, Gopferich A. Polymer coating of quantum dots—a powerful tool toward diagnostics and sensorics. Eur J Pharm Biopharm. 2008;68:138–152
  103. Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett. 2004;4:11–18
  104. Chan WH, Shiao NH, Lu PZ. CdSe quantum dots induce apoptosis in human neuroblastoma cells via mitochondrial-dependent pathways and inhibition of survival signals. Toxicol Lett. 2006;167:191–200
  105. Oh SH, Lim SC. A rapid and transient ROS generation by cadmium triggers apoptosis via caspase-dependent pathway in HepG2 cells and this is inhibited through N-acetylcysteine-mediated catalase upregulation. Toxicol Appl Pharmacol. 2006;212:212–223
  106. So MK, Xu C, Loening AM, Gambhir SS, Rao J. Self-illuminating quantum dot conjugates for in vivo imaging. Nat Biotechnol. 2006;24:339–343
  107. Cai W, Shin DW, Chen K, Gheysens O, Cao Q, Wang SX, et al. Peptide-labeled near-Infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 2006;6:669–676
  108. Wu X, Liu H, Liu J, Haley KN, Treadway JA, Larson JP, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular target with semiconductor quantum dots. Nat Biotechnol. 2002;21:41–46
  109. Goldman ER, Anderson GP, Tran PT, Mattoussi H, Charles PT, Mauro JM. Conjugation of luminescent quantum dots with antibodies using an engineered adaptor protein to provide new reagents for fluoroimmunoassay. Anal Chem. 2002;74:841–847
  110. Tully E, Hearty S, Leonard P, Okennedy R. The development of rapid fluorescence-based immunoassays, using quantum dot-labelled antibodies for the detection of Listeria monocytogenes cell surface proteins. Int J Biol Macromol. 2006;39:127–134
  111. Zhu L, Ang S, Liu WT. Quantum dots as a novel immunofluorescent detection system for Cryptosporidium parvum and Giardia lamblia. Appl Environ Microbiol. 2004;70:597–598
  112. Goldman ER, Clapp AR, Anderson GP, Uyeda HT, Mauro JM, Medintz IL, et al. Multiplexed toxin analysis using four colors quantum dot fluororeagents. Anal Chem. 2004;76:684–688
  113. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release. 2005;109:169–188
  114. Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release. 2008;126:187–204
  115. Lee ES, Oh KT, Kim D, Youn YS, Bae YH. Tumor pH-responsive flower-like micelles of poly (L-lactic acid)-b-poly (ethylene glycol)-b-poly(L-histidine). J Control Release. 2007;123:19–26
  116. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release. 2005;103:405–418
  117. Wang CH, Hsiue GH. Polymeric micelles with a pH-responsive structure as intracellular drug carriers. J Control Release. 2005;108:140–149
  118. Husseini GA, Myrup GD, Pitt WG, Christensen DA, Rapoport NY. Factors affecting acoustically triggered release of drugs from polymeric micelles. J Control Release. 2000;69:43–52
  119. Munshi N, Rapoport N, Pitt WG. Ultrasonic activated drug delivery from Pluronic P- 105 micelles. Cancer Lett. 1997;118:13–19
  120. Myhr G, Moan J. Synergistic and tumour selective effects of chemotherapy and ultrasound treatment. Cancer Lett. 2006;232:206–213
  121. Howard B, Gao A, Lee SW, Seo M, Rapoport N. Ultrasound enhanced chemotherapy of drug-resistant breast cancer tumors by micellar-encapsulated paclitaxel. Am J Drug Deliv. 2006;4:97–104
  122. Nakayama M, Okano T, Miyazaki T, Kohori F, Sakai K, Yokoyama M. Molecular design of biodegradable polymeric micelles for temperature-responsive drug release. J Control Release. 2006;115:46–56
  123. Nakayama M, Chung JE, Miyazaki T, Yokoyama M, Sakai K, Okano T. Thermal modulation of intracellular drug distribution using thermoresponsive polymeric micelles. React Funct Polym. 2007;67:1398–1407
  124. Lasic DD. Sterically stabilized liposomes in cancer therapy and gene delivery. Curr Opin Mol Ther. 1999;1:177–185
  125. Pain D, Das PK, Ghosh PC, Bachhawat BK. Increased circulatory half-life of liposomes after conjugation with dextran. J Biosci. 1984;6:811–816
  126. Torchilin VP, Levchenko TS, Whiteman KR, Yaroslavov AA, Tsatsakis AM, Rizos AK. Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification. Biomaterials. 2001;22:3035–3044
  127. Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S, et al. Targeted nanoparticles for cancer therapy. Nano Today. 2007;2:14–21
  128. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–284
  129. Farokhzad OC, Jon S, Khademhosseini A, Tran TT, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004;64:7668–7672
  130. Bhadra D, Bhadra S, Jain S, Jain NK. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm. 2003;257:111–124
  131. Mehren MV, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annu Rev Med. 2003;54:343–369
  132. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer. 2004;90:561–565
  133. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev. 2004;56:1127–1141
  134. Antony AC. The biological chemistry of folate receptors. J Am Soc Hematol. 1992;79:2807–2820
  135. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002;54:675–693
  136. Sudimack JBA, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41:147–162
  137. Rege BD, Kao JPY, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci. 2002;16:237–246
  138. Pan J, Feng SS. Targeted delivery of paclitaxel using folate-decorated poly (lactide) evitamin E TPGS nanoparticles. Biomaterials. 2008;29:2663–2672
  139. Oyewumi MO, Mumper RJ. Influence of formulation parameters on gadolinium entrapment and tumor cell uptake using folate-coated nanoparticles. Int J Pharm. 2003;251:85–97
  140. Kohler G, Milstein C. Continuous culture of fused cell secreting antibody of predefined specificity. Nature. 1975;256:495–497
  141. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release. 2007;120:18–26
  142. Steinhauser I, Spankuch B, Strebhardt K, Langer K. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials. 2006;27:4975–4983
  143. Sievers EL, Larson RA, Stadtmauer EA, Estey E. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244–3254
  144. Bross PF, Beit J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490–1496
  145. Lee JF, Hesselberth JR, Meyers LA, Ellington AD. Aptamer database. Nucleic Acids Res. 2004;32:95–100
  146. Gold L, Tuerk C. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249:505–510
  147. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 2008;24:442–449
  148. Sampson T. Aptamers and SELEX: the technology. World Pat Inf. 2003;25:123–129
  149. Phillips JA, Lopez-Colon D, Zhu Z, Xu Y, Tan W. Applications of aptamers in cancer cell biology. Anal Chim Acta. 2008;621:101–108
  150. Lee JF, Stovall GM, Ellington AD. Aptamer therapeutics advance. Curr Opin Chem Biol. 2006;10:282–289
  151. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev. 2005;57:2106–2129
  152. Yang W, Cheng Y, Xu T, Wang X, Wen L. Targeting cancer cells with biotin-dendrimer conjugates. Eur J Med Chem. 2008;1–7
  153. Yiyun C, Tongwen X, Rongqiang F. Polyamidoamine dendrimers used as solubility enhancers of ketoprofen. Eur J Med Chem. 2005;40:1390–1393
  154. Singh B, Florence AT. Hydrophobic dendrimer-derived nanoparticles. Int J Pharm. 2005;298:348–353
  155. Vandamme TF, Brobeck L. Poly (amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release. 2005;102(1):23–38
  156. Dufes C, Uchegbu IF, Schatzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev. 2005;57:2177–2202
  157. Mousa SA. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr Opin Chem Biol. 2002;6:534–541
  158. Lim EH, Danthi TN, Bednarski M, Li KCP. A review: integrin αvβ3-targeted molecular imaging and therapy in angiogenesis. Nanomedicine. 2005;1:110–114
  159. Dufes C, Olivier J, Gaillard F, Gaillard A, Couet W, Muller J. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm. 2003;255:87–97
  160. Wernig K, Griesbacher M, Andreae F, Hajos F, Wagner J, Mosgoeller W, et al. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles. J Control Release. 2008;130:192–198
  161. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007;9:128–147
  162. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56:1649–1659

PII: S1549-9634(09)00094-X

doi: 10.1016/j.nano.2009.04.008

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 1 , Pages 9-24 , February 2010

Article Tools

* Image Usage & Resolution